Wire · opportunities
FDA makes acting CDER, CBER chiefs permanent
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 9 September 2026 · Fusion42 review
The FDA has appointed the acting chiefs of its Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) as permanent leaders, signalling a stabilisation in its regulatory leadership.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You need to recalibrate your FDA engagement strategies as the permanent leaders of CDER and CBER set predictable regulatory priorities. This creates a clearer path for your product development and compliance planning in US biotech.
◆ Coverage
2 sources · 9 Sep 2026
◆ Related on Wire
◆ Topics
Biotechfdadrug-regulationbiologicsleadershipus-healthcare